MARK HARVEY: Open Payments
NPI 1992947287 · GRAND ISLAND, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,533 in 78 payments from 16 companies in 2025. Trend: 2023 $417 · 2024 $974 · 2025 $1,533
Food & beverage: $1,533
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $428 |
| Otsuka America Pharmaceutical, Inc. | 13 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $186 |
| Janssen Pharmaceuticals, Inc | 5 | $180 |
| E.R. Squibb & Sons, L.L.C. | 11 | $154 |
| JAZZ PHARMACEUTICALS INC. | 5 | $97 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Tris Pharma Inc | 1 | $26 |
Products named: VRAYLAR, CAPLYTA, COBENFY, ABILIFY MAINTENA, SPRAVATO, REXULTI, XYWAV, UZEDY.
Industry payments across NE — which companies pay providers there.
